Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Total Liabilities data on file, last reported at $361.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 7.9% year-over-year to $361.5 million; the trailing twelve-month figure through Mar 2026 stood at $361.5 million (up 7.9% YoY), and the FY2025 full-year result was $401.4 million, up 18.05% from the prior year.
• Total Liabilities declined to $361.5 million in Q1 2026, from $401.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $401.4 million in Q4 2025 to a low of $249.5 million in Q1 2022.
• A 5-year average of $317.4 million and a median of $331.3 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities climbed 27.09% in 2023 and retreated 1.28% in 2024, its largest moves.
• Tracing HRMY's Total Liabilities over 5 years: stood at $271.0 million in 2022, then rose by 27.09% to $344.5 million in 2023, then dropped by 1.28% to $340.0 million in 2024, then advanced by 18.05% to $401.4 million in 2025, then dropped by 9.95% to $361.5 million in 2026.
• Business Quant data shows HRMY's Total Liabilities at $361.5 million in Q1 2026, $401.4 million in Q4 2025, and $373.1 million in Q3 2025.